Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

US Patent 11572408 · Granted Feb 7, 2023

Estimated economic value: $620,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CCR8 antibodies and uses thereof2025
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy2025
Use of semaphorin-4D antibodies in combination with an immune modulating therapy2024
Use of semaphorin-4D antibodies in combination with an immune modulating therapy2024
Use of semaphorin-4D antibodies in combination with an immune modulating therapy2024
Anti-CD100 antibodies and methods for using the same2024
Human anti-semaphorin 4D antibody2024
Human anti-semaphorin 4D antibody2024
Anti-CXCL13 antibodies and methods of using the same2024
Integral membrane protein display on poxvirus extracellular enveloped virions2024
Anti-CCR8 antibodies and uses thereof2024
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy2023